White House blocks NIH from awarding any research grants
Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT…
Vinay Prasad departs FDA | STAT
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
UnitedHealth issues new, lower 2025 profit forecasts
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences…
FDA clears way for Sarepta Therapeutics to use Duchenne drug in some patients
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
Medicare Savings Programs face cut, hospitals and insurers report Q2 results
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences…
He took an ALS drug before getting sick — and it may have worked
For over an hour, Jeff Vierstra lay still in Columbia University’s ALS clinic, as a doctor poked him…
As Sarepta, FDA tangle over Duchenne therapy, families are caught in the middle
Jennifer Hill Blair recognized the Cincinnati number on her buzzing phone and slipped out of the school meeting,…
Sarepta Therapeutics’ Elevidys faces ‘arduous’ path back to market
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
Rescission package vote casts shadow over health care initiatives
WASHINGTON — Congressional Republicans early on Friday morning passed legislation to take back money they had already appropriated…
GSK’s blood cancer drug Blenrep hits setback with FDA advisers
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting move
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
We’re reading about GLP-1 drugs for addiction, FDA funding
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating,…